1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAACR-Sontag Foundation Brain Cancer Research Fellowship is sponsored by American Association for Cancer Research (AACR). Supports postdoctoral or clinical research fellows conducting brain cancer research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
AACR-Sontag Foundation Brain Cancer Research Fellowship | Grants | AACR AACR Call to Action Concerning OMB Proposal to Rewrite the Rules for Scientists and Physicians Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. To further refine your search, toggle appropriate sections on or off.
Patient / Caregivers / Public Researchers / Professionals AACR-Sontag Foundation Brain Cancer Research Fellowship The AACR-Sontag Foundation Brain Cancer Research Fellowship represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct brain cancer research and to establish a successful career path in this field.
The proposed project may be basic, clinical, translational, or epidemiological in nature and must have direct applicability and relevance to brain cancer. Siva Kumar Natarajan, PhD Elucidating the Oncogenic Role of Itaconate in Aggressive, ZFTA-RELA Fusion-Driven Ependymomas Scientific Statement of Research More than 70% of childhood hemispheric ependymomas bear recurrent ZFTA-RELA fusions.
Despite existing knowledge of the underlying molecular drivers, there are no effective treatments, targeted therapies, or clinical trials for ZFTA-RELA ependymomas. Previous unbiased metabolomic studies identified elevated itaconate production to be an important metabolic pathway in these cells.
Dr. Natarajan aims to define molecular mechanisms of ZFTA-RELA fusion-driven itaconate metabolism and determine the therapeutic potential of inhibiting itaconate production in these tumors. Dr. Natarajan received his doctoral degree in molecular and cellular pathology from the University of Michigan, studying how altered metabolism shapes the epigenetic landscape in posterior fossa ependymomas and IDH1-mutant gliomas.
He is currently a postdoctoral fellow at the University of Michigan where his goal is to determine how itaconate, an immunomodulatory metabolite, is a central driver of aggressive, ZFTA-RELA fusion ependymomas. Acknowledgement of Support “My vision involves pursuing an academic career focused on cancer research.
I aspire to merge my expertise in tumor immunology and metabolism to explore how tumor-derived metabolites promote aggressive pediatric brain tumors. The AACR-Sontag Foundation Brain Cancer Research Fellowship is a significant opportunity that will enrich my academic journey and provide a platform to learn from esteemed leaders in pediatric cancer biology.
I am immensely honored and grateful to be a part of both AACR and the Sontag Foundation. ” University of California, San Francisco San Francisco, California, USA Targeting epigenetic drivers in group 3 medulloblastoma Medulloblastoma (MB), the most common malignant brain tumor in children, arises in the cerebellum.
Group 3 (G3) MBs show poor overall survival (<50%) and recurrent metastases within the central nervous system and have frequent amplifications of both MYC and TGFβ pathway effectors. Remarkably, some tumors have no reported mutations, suggesting roles for aberrant epigenetic mechanisms in remodeling the transcriptional landscape of G3MB.
Dr. Qadeer is utilizing a unique model of MYC-driven G3MB based on human induced pluripotent stem cells differentiated to neuroepithelial stem cells to investigate therapeutic vulnerabilities. Dr. Qadeer will investigate the chromatin landscape of G3MB and screen for epigenetic factors that cooperate with MYC to promote therapy resistance using high-resolution Perturb-seq.
This technique combines multiplexed CRISPRi with scRNA-seq, integrating genetic/therapeutic perturbations to transcription phenotypes. Dr. Qadeer completed her doctorate in Biomedical Sciences at Icahn School of Medicine at Mount Sinai investigating epigenetic dysregulation in neuroblastoma.
She is currently a postdoctoral fellow at University of California, San Francisco, where her studies focus on utilizing innovative humanized stem cell-based models to identify drivers of medulloblastoma progression. Her goal is to understand the chromatin and transcriptional landscape of these tumors and to integrate these findings to identify new targets to overcome resistance and recurrence.
Dr. Qadeer was a recipient of the Damon Runyon-Sohn Pediatric Cancer Fellowship as well as the Alex Lemonade Stand Foundation Young Investigator award. Acknowledgment of Support “I am immensely honored to receive the 2023 AACR-Sontag Foundation Brain Cancer Research Fellowship. This award will help me build the foundation for my independent scientific career and make an impact in pediatric brain tumors.
I am grateful to be a part of the incredible AACR, and Sontag research communities. ” block needs to be placed in the location where the link block will be displayed--> AACR-AstraZeneca Cancer Research Fellowships Research Training and Fellowships
According to the current listing, eligibility includes: Postdoctoral or clinical research fellows at academic, medical, or non-profit research institutions. Confirm the full requirements in the official notice before applying.
The current listing shows $130,000 over two years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
AACR-Sontag Foundation Brain Cancer Research Fellowship is funded by American Association for Cancer Research (AACR). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article